Latest papers

[Efficacy of entecavir and adefovir combination therapy in patients with chronic hepatitis B refractory to lamivudine and adefovir combination therapy].

Antiviral drugs for influenza.

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Of lives and livers: emerging responses to the hepatitis C virus.

[Etiotropic therapy of influenza: lessons from the last pandemic].

Chronic hepatitis B in Asia-new insights from the past decade.

Rapid identification of YVDD mutants of hepatitis B virus using smart amplification process with competition probe.

Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection.

Update: influenza activity --- United States, October 3-December 11, 2010.

Genetic characterization of circulating seasonal Influenza A viruses (2005-2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India.

Population-based monitoring of HIV drug resistance in Namibia with early warning indicators.

Meeting of the WHO working group on polymerase chain reaction protocols for detecting subtype influenza A viruses – Geneva, June 2010.

Management of influenza.

Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel.

Influenza in the tropics.

Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification.

Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation.

Molecular methods in the diagnosis and management of chronic hepatitis B.

Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.

[Current anti-influenza virus chemotherapy].